undefined undefined
NaN.000
NaN.00%
Analyst Thomas Smith of Leerink Partners reiterated a Buy rating on Madrigal Ph...
56分钟前
摩根大通证券公司:维持Madrigal Pharmaceuticals(MDGL.US)评级,由优于大市调整至优于大市评级, 目标价由397.00美元调整至3...
05-09 02:02
JMP Securities analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and lowers the price target from $397 to $381.
05-09 02:00
Madrigal Pharmaceuticals Inc (MDGL) has shared an update. Madrigal Pharmaceutic...
05-08 04:52
With its Q1 2024 results on Tuesday, Madrigal Pharmaceuticals (NASDAQ:MDGL) issued encouraging remarks on the initial uptake for its newly approved liver disease drug Rezdiffra, noting a "tremendous i...
05-07 22:44
Gainers FibroGen (NASDAQ:FGEN) shares rose 37.1% to $1.59 during Tuesday's pre...
05-07 20:06
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(7.38) per share which missed the analyst consensus estimate of $(6.17) by 19.61 percent.
05-07 19:21
Major earnings expected before the bell on Tuesday include: BP p.l.c. (BP) Datadog (DDOG) The Walt Disney (DIS) Duke Energy (DUK) Nikola (NKLA) Other earnings slated for release before Tuesday's open ...
05-06 23:08
Unity Software(U.US) reported fourth-quarter financial results after the market...
04-22 18:18
Madrigal Pharmaceuticals (NASDAQ:MDGL) said that its recently approved NASH/MASH drug Rezdiffra is now available in the US through a specialty pharmacy network. Rezdiffra, also known as resmetirom, re...
04-09 22:03